Trial Profile

Phase I single ascending dose trial of deuterium-modified ivacaftor for the treatment of cystic fibrosis.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 02 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deutivacaftor (Primary) ; Ivacaftor
Indications Cystic fibrosis
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

28 Apr 2016 Results published in Concert Pharmaceuticals media release.
08 Oct 2015 Results published in a Concert Pharmaceuticals media release.
22 Sep 2015 The data from this trial will be presented in the poster session at the North American Cystic Fibrosis Conference, according to a Concert Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com